Background Ovarian cancer is characterized by high mortality, extensive genomic instability driven by copy number alterations, and a highly immunosuppressive tumor microenvironment. Increasing evidence suggests that chronic inflammation and stromal–immune interactions contribute to tumor progression and therapeutic resistance. Bradykinin receptor B1 (BDKRB1), an inflammation‐inducible G protein–coupled receptor, has been implicated in tumor‐associated inflammatory signaling; however, its genomic determinants and immunological relevance in ovarian cancer remain poorly defined. Methods We performed an integrative multiomics analysis of BDKRB1 using TCGA‐OV and multiple independent GEO cohorts. The analytical framework incorporated bulk transcriptomics, copy number variation profiling, single‐cell RNA sequencing, immune cell deconvolution, pathway enrichment analysis (GSEA, GSVA, and PROGENy), and pharmacogenomic modeling. Patients were dichotomized into BDKRB1‐high and BDKRB1‐low groups using cohort‐specific median expression to ensure cross‐dataset consistency. Associations with genomic instability, TME features, and drug response patterns were systematically evaluated. Quantitative real‐time polymerase chain reaction (qRT‐PCR) was further performed to validate BDKRB1 expression in ovarian cancer cell lines. Results BDKRB1 was consistently overexpressed in ovarian cancer and associated with unfavorable clinical outcomes across multiple cohorts. Elevated BDKRB1 expression correlated with increased genomic instability, reflected by higher fractions of the genome altered, gained, and lost. Although copy number variation partially explained BDKRB1 upregulation, the modest correlation suggested additional regulatory mechanisms. Tumors with high BDKRB1 expression exhibited immunosuppressive microenvironmental features, including enrichment of cancer‐associated fibroblasts and reduced estimated CD8 + T‐cell infiltration, despite concurrent activation of inflammatory signaling pathways. Single‐cell transcriptomic analysis further identified fibroblasts as a major cellular source of BDKRB1 expression. Functional analyses indicated associations between BDKRB1 and inflammatory signaling, metabolic pathways, and oncogenic programs. Pharmacogenomic analyses suggested distinct drug sensitivity patterns in BDKRB1‐high tumors and identified fasudil as a potential candidate compound for reversing BDKRB1‐associated transcriptional signatures. Conclusion This integrative analysis identifies BDKRB1 as a microenvironment‐associated marker linking genomic instability with inflammatory and immunosuppressive tumor ecosystems in ovarian cancer. Although the findings are primarily associative, they provide a systems‐level perspective on immune evasion mechanisms and highlight BDKRB1 as a potential biomarker for TME characterization and therapeutic hypothesis generation.
Pu et al. (2026) studied this question.